Last 12 months
Inside the activity.
0 purchase rows · 34 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 22, 2022 21:07 UTC |
Colangelo DominickDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 2,865 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,865 Underlying: Common Stock · 2,865 shares Expires 2032-02-18 F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:04 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 61,404 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000513 · primary_01.xml · derivative · entry 3 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,404 Underlying: Common Stock · 61,404 shares Expires 2032-02-18 F4 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:04 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 2,865 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000513 · primary_01.xml · derivative · entry 2 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,865 Underlying: Common Stock · 2,865 shares Expires 2032-02-18 F4 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:04 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 11,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000513 · primary_01.xml · derivative · entry 1 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,018 Underlying: Common Stock · 11,018 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F3 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2022 Filed Mar 11, 2022 21:06 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 1,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000721 · primary_01.xml · derivative · entry 2 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,679 Underlying: Common Stock · 1,679 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 18, 2022 Filed Mar 11, 2022 21:06 UTC |
SIEGAL JONATHANPrincipal Accounting Officer
|
GrantStock Option (right to buy) · Derivative | 4,198 | $0.00 Strike: $34.90 | $0.00 |
DisclosureSEC source: 0001593968-22-000721 · primary_01.xml · derivative · entry 1 SIEGAL JONATHAN · CIK 0001916145 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,198 Underlying: Common Stock · 4,198 shares Expires 2032-02-18 F1 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:52 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,625 | $35.26 | $57,297.50 |
DisclosureSEC source: 0001593968-22-000470 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 1,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:52 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 775 | $35.26 | $27,326.50 |
DisclosureSEC source: 0001593968-22-000470 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,894 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:52 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000470 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $35.26 | $264,450.00 |
DisclosureSEC source: 0001593968-22-000468 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 3,251 | $35.26 | $114,630.26 |
DisclosureSEC source: 0001593968-22-000468 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,370 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000468 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:51 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $35.26 | $123,410.00 |
DisclosureSEC source: 0001593968-22-000469 · primary_01.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:51 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 1,564 | $35.26 | $55,146.64 |
DisclosureSEC source: 0001593968-22-000469 · primary_01.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,683 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:51 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000469 · primary_01.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2023, and February 11, 2024, respectively. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:04 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 650 | $33.91 | $22,041.50 |
DisclosureSEC source: 0001593968-22-000423 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:04 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 310 | $33.91 | $10,512.10 |
DisclosureSEC source: 0001593968-22-000423 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,044 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:04 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000423 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:02 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $33.91 | $63,581.25 |
DisclosureSEC source: 0001593968-22-000422 · primary_01.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:02 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 931 | $33.91 | $31,570.21 |
DisclosureSEC source: 0001593968-22-000422 · primary_01.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,747 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:02 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000422 · primary_01.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:01 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,937 | $33.91 | $235,233.67 |
DisclosureSEC source: 0001593968-22-000421 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,938 Underlying: Common Stock · 6,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:01 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 3,049 | $33.91 | $103,391.59 |
DisclosureSEC source: 0001593968-22-000421 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,121 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2022 Filed Feb 8, 2022 22:01 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 6,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000421 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest on February 6, 2023. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:05 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,000 | $39.30 | $157,200.00 |
DisclosureSEC source: 0001593968-22-000058 · primary_01.xml · derivative · entry 3 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F5 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 25, 2021. F6 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:05 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Tax withholdingCommon Stock | 1,174 | $39.30 | $46,138.20 |
DisclosureSEC source: 0001593968-22-000058 · primary_01.xml · nonDerivative · entry 2 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,613 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:05 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000058 · primary_01.xml · nonDerivative · entry 1 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on January 25, 2021. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.66 | $0.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 10,000 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase a total of 26,000 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 6, 2019. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,604 Underlying: Common Stock · 9,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 5,881 | $40.08 | $235,692.25 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,547 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $16.66 | $166,600.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 9,000 | $40.14 | $361,237.50 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,428 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 9,000 | $10.95 | $98,550.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,604 Underlying: Common Stock · 1,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 1,000 | $40.00 | $40,000.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,428 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 23:54 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 1,000 | $10.95 | $10,950.00 |
DisclosureSEC source: 0001593968-21-002569 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:07 UTC |
GILMAN STEVEN CDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-21-002478 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:07 UTC |
GILMAN STEVEN CDirector
|
SaleCommon Stock | 5,000 | $39.17 | $195,855.00 |
DisclosureSEC source: 0001593968-21-002478 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 21:07 UTC |
GILMAN STEVEN CDirector
|
Exercise / conversionCommon Stock | 5,000 | $3.74 | $18,700.00 |
DisclosureSEC source: 0001593968-21-002478 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 20:12 UTC |
GILMAN STEVEN CDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-21-002304 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 20:12 UTC |
GILMAN STEVEN CDirector
|
SaleCommon Stock | 5,000 | $50.57 | $252,870.00 |
DisclosureSEC source: 0001593968-21-002304 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021. Read SEC document |
| October 27, 2021 Filed Oct 28, 2021 20:12 UTC |
GILMAN STEVEN CDirector
|
Exercise / conversionCommon Stock | 5,000 | $3.74 | $18,700.00 |
DisclosureSEC source: 0001593968-21-002304 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 20:09 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-21-002303 · primary_01.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,063 Underlying: Common Stock · 10,000 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on April 10, 2018, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 20:09 UTC |
Halpin MichaelChief Operating Officer
|
SaleCommon Stock | 10,000 | $50.57 | $505,689.00 |
DisclosureSEC source: 0001593968-21-002303 · primary_01.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,696 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2021. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 26, 2021 Filed Oct 28, 2021 20:09 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 10,000 | $2.65 | $26,500.00 |
DisclosureSEC source: 0001593968-21-002303 · primary_01.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:13 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,000 | $48.80 | $195,200.00 |
DisclosureSEC source: 0001593968-21-002215 · primary_01.xml · derivative · entry 3 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F5 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 25, 2021. The remaining RSUs will vest on December 31, 2021. F6 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:13 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Tax withholdingCommon Stock | 1,174 | $48.80 | $57,291.20 |
DisclosureSEC source: 0001593968-21-002215 · primary_01.xml · nonDerivative · entry 2 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:13 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-002215 · primary_01.xml · nonDerivative · entry 1 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on January 25, 2021. The remaining RSUs will vest on December 31, 2021. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:12 UTC |
GILMAN STEVEN CDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-21-002214 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:12 UTC |
GILMAN STEVEN CDirector
|
SaleCommon Stock | 5,000 | $48.85 | $244,255.00 |
DisclosureSEC source: 0001593968-21-002214 · primary_01.xml · nonDerivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 30, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.